10X Genomics Stock

10X Genomics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of 10X Genomics (TXG) as of Aug 20, 2026 is -110.89 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -194.56 M USD — a change of -43.01% (higher).

EBITDA

-110.89 MUSD

YoY

-43.01%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of 10X Genomics is 2026 -110.89 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of 10X Genomics was 2025 -194.56 M USD. It decreases by -43.01% higher compared to the previous year.
Access this data via the Eulerpool API

10X Genomics Stock analysis

What does 10X Genomics do? 10X Genomics is a US-based company specializing in the development of life science products. It was founded in 2012 by Serge Saxonov and Ben Hindson and is headquartered in Pleasanton, California. The company's business model focuses on providing technology platforms that enable researchers and scientists to analyze and understand complex biological data. It combines microfluidics, genomics, and bioinformatics. 10X Genomics is divided into different divisions, each focusing on different products and applications: Single-Cell Genomics, Long-Read Sequencing, Immune Profiling, and Spatial Transcriptomics. The company's products include the Chromium platform for cell type identification, disease research, and drug screening; Long-Read Sequencing technology for reading larger DNA fragments; tools and solutions for immune profiling and understanding the immune system; and Spatial Transcriptomics technology for studying the spatial organization of gene expression in tissues. 10X Genomics also offers other products and solutions in the field of genomic sequencing and analysis, including DNA preparation and sequencing kits, software for DNA data analysis and interpretation, and consulting and training services. The company has received various awards and recognition for its innovative approach, including the Innovation Award from The Scientist magazine and the Disruptive Technology Award from the Wall Street Journal. Overall, 10X Genomics has become a leading company in the life science industry, contributing to the advancement of scientific understanding and supporting progress in medicine and biotechnology. 10X Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 10X Genomics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of 10X Genomics is -110.89 M USD in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of 10X Genomics changed from -194.56 M USD to -110.89 M USD, representing a -43.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) 10X Genomics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s 10X Genomics historically and in real time.

Access this data via the Eulerpool API

Income Statement — 10X Genomics

All Key Metrics — 10X Genomics